Medifast Reports Significant Revenue Decline and Operational Losses in Q3 2025

Medifast, Inc. reported a significant decline in financial performance for the third quarter and the first nine months of 2025, as detailed in its latest 10-Q filing. For the three months ended September 30, 2025, the company generated revenue of $89.4 million, a decrease of 36.2% from $140.2 million in the same period of 2024. The nine-month revenue also fell by 35.7% to $310.7 million from $483.5 million year-over-year. The decline in revenue was primarily attributed to a reduction in the number of active earning OPTAVIA coaches, which decreased by 35% to 19,500 from 30,000 in the prior year, reflecting ongoing challenges in client acquisition.

The company's gross profit for the third quarter was $62.2 million, down 41.2% from $105.7 million a year earlier, with gross profit margins declining to 69.5% from 75.4%. For the nine months, gross profit decreased to $223.0 million, a 37.4% drop compared to the previous year. Medifast reported a loss from operations of $4.1 million for the third quarter, compared to an income of $2.1 million in the same quarter of 2024. The nine-month loss from operations was $6.4 million, a stark contrast to the $2.2 million profit recorded in the prior year.

In terms of operational metrics, the average revenue per active earning OPTAVIA coach decreased by 1.9% to $4,585 for the third quarter, continuing a downward trend since the third quarter of 2022. The company has been facing increased competition from GLP-1 medications, which have gained popularity as weight-loss solutions, further complicating client acquisition efforts. Medifast's strategic response includes enhancing its product offerings and coach support systems to better align with market demands.

On the balance sheet, Medifast reported total assets of $268.2 million as of September 30, 2025, down from $284.2 million at the end of 2024. The company maintained stockholders' equity of $214.7 million, a slight increase from $210.1 million at the end of the previous year. Cash and cash equivalents rose to $99.5 million, reflecting a focus on liquidity amid challenging market conditions. The company also noted a decrease in net cash provided by operating activities, which fell to $12.1 million for the nine months ended September 30, 2025, down from $29.4 million in the same period of 2024.

Looking ahead, Medifast is focused on a strategic transformation aimed at enhancing coach productivity and client engagement. The company plans to launch new product innovations and improve its digital tools to support coaches and clients. Despite the current challenges, Medifast remains committed to its mission of promoting metabolic health and believes that its integrated, coach-supported model will position it for future growth in the evolving weight-loss market.